Madhu Arora, MD
Rheumatology · Yuma, AZNPI 1497702484
Payments from drug & device makers
What this record shows
8 manufacturers reported payments, led by GSK at 47.4% of the total. Reporting peaked in 2019 at $230 and has fallen 91.6% since, to $19 in 2024. That places this record below the midpoint for rheumatology clinicians in AZ, where the typical reported total is $3,203.
Across 12 payments — averaging $50.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$287
- Genentech USA, Inc.$99
- Johnson & Johnson$67
- Genentech, Inc.$40
- Sobi, Inc$39
- Lilly USA, LLC$35
- plus $40 from 2 others
What the payments were for
- Food & beverage$28747%
- Education$31953%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $287 |
| Genentech USA, Inc. | 1 | $99 |
| Johnson & Johnson | 1 | $67 |
| Genentech, Inc. | 1 | $40 |
| Sobi, Inc | 2 | $39 |
| Lilly USA, LLC | 1 | $35 |
| Amgen | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BENLYSTA$140
How this compares
$607 in reported general payments places this provider in the 30th percentile of 102 rheumatology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Colchicine | 44 | $2,849 |
| Sulfasalazine DrSulfasalazine | 79 | $2,679 |
| Hydroxychloroquine Sulfate | 71 | $2,363 |
| Duloxetine Hcl | 113 | $2,257 |
| MethotrexateMethotrexate Sodium | 77 | $2,052 |
| Leflunomide | 43 | $1,601 |
| Celecoxib | 44 | $1,541 |
| Sulindac | 37 | $936 |
| Prednisone | 73 | $545 |
| Meloxicam | 48 | $422 |
| Folic Acid | 17 | $368 |
| Allopurinol | 24 | $287 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Yuma
- Sherif NasefYuma$111K
- Nehad SolomanPhoenix$1.3M
- John TesserPhoenix$999K
- Joy SchechtmanPeoria$860K
- Mona AminGlendale$446K
- Brittany PanicoGilbert$374K
- Amer Al-KhoudariChandler$369K
- Andrew SharobeemGlendale$231K
- Paul HowardScottsdale$124K
- Michael MaricicTucson$110K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.